Ocular Therapeutix

Ocular Therapeutix

Yahoo Finance • 13 hours ago

3 Unprofitable Stocks Walking a Fine Line

3 Unprofitable Stocks Walking a Fine Line Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.... Full story

Yahoo Finance • 4 days ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular" or the "Company"), an integrated biopharmaceutical company committed to redefining the retina experience, today an... Full story

Yahoo Finance • 20 days ago

Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?

In the high-stakes realm of clinical-stage biotechnology, long-term shareholder value is fundamentally forged by pipeline assets that solve deep-seated clinical bottlenecks while offering significant pricing power and capital efficiency. O... Full story

Yahoo Finance • 28 days ago

Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges

1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnat... Full story

Yahoo Finance • 2 months ago

Ocular gains on EyePoint phase 3 wet AMD miss

[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * Ocular Therapeutix (OCU... Full story

Yahoo Finance • 2 months ago

3 Healthcare Stocks with Questionable Fundamentals

3 Healthcare Stocks with Questionable Fundamentals From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial p... Full story

Yahoo Finance • 2 months ago

3 Russell 2000 Stocks That Concern Us

3 Russell 2000 Stocks That Concern Us The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher vol... Full story

Yahoo Finance • 3 months ago

William Blair updates conviction list: Oracle in, Meta out and more

[Technology background image, graph, displaying analytical data about stock trading.] Donny DBM William Blair added Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), American Express (AXP [https://seekingalpha.com/symbol/AXP]), Ecolab... Full story

Yahoo Finance • 3 months ago

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming... Full story

Yahoo Finance • 4 months ago

Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Ocular Therapeuticx, Inc. (NASDAQ:OCUL) is among the best healthcare stocks. TheFly reported on June 18 that H.C. Wainwright increased... Full story

Yahoo Finance • 4 months ago

Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?

Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings? Over the past six months, Ocular Therapeutix's shares (currently trading at $10.37) have posted a disappointing 18.5% loss, well below the S&P 500's 7.8% gain. This was partl... Full story

Yahoo Finance • 4 months ago

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across S... Full story

Yahoo Finance • 5 months ago

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Key Points Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million. Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales an... Full story

Yahoo Finance • 5 months ago

Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the 10 best biotech stocks with highest upside potential. On April 13, William Blair maintained an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) right after the presentation of addit... Full story

Yahoo Finance • 6 months ago

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

BEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced plans to host an Investor Day on... Full story

Yahoo Finance • 6 months ago

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have outperformed the market lately as the 1.1% drawdown for healthcare stocks over the p... Full story

Yahoo Finance • 7 months ago

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools

Key Points VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both tradi... Full story

Yahoo Finance • 7 months ago

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix(NASDAQ:OCUL), an estimated $71.01 million trade based on quarterly average pricing. VR... Full story

Yahoo Finance • 7 months ago

3 of Wall Street’s Favorite Stocks We’re Skeptical Of

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about com... Full story